不同AFP水平下血清IL-1与肝癌根治术后早期复发和预后的关系

邓伟伟; 朱文明; 易超; 冯阳春; 黄艳春

doi:10.3969/j.issn.1001-5256.2018.02.016

不同AFP水平下血清IL-1与肝癌根治术后早期复发和预后的关系

DOI: 10.3969/j.issn.1001-5256.2018.02.016

1. 新疆医科大学附属肿瘤医院检验科
2. 新疆心脑血管病医院ICU
3. 新疆医科大学附属肿瘤医院肝胆外科

基金项目:

新疆医科大学科研创新基金(XYDCX201558)；

详细信息

中图分类号: R735.7
计量
- 文章访问数: 374
- HTML全文浏览量: 17
- PDF下载量: 71
- 被引次数: 0
出版历程
- 出版日期: 2018-02-20

Association of serum interleukin-17 level with early recurrence and prognosis after radical surgery in hepatocellular carcinoma patients with different levels of alpha-fetoprotein

Department of Clinical Laboratory, The Affiliated Tumor Hospital of Xinjiang Medical University

Research funding:

摘要

摘要:
目的研究IL-17在不同AFP水平下的HBV相关肝细胞癌（HCC）中的表达情况以及其与HCC根治术后复发和预后的关系。方法收集新疆医科大学附属肿瘤医院2013年1月-2014年12月收治的HBV相关HCC行根治切除术的连续病例167例,另外选取肝血管瘤患者115例（其中HBV携带者83例）作为对照组。采用ELISA法检测167例HBV相关HCC血清中IL-17表达,采用电化学发光法检测血清AFP浓度,并分析IL-17的表达与不同AFP水平的关联性及其与HBV相关HCC患者根治切除术后复发和生存的关系。计数资料组间比较采用χ2检验,生存分析采用Kaplan-Meier相关性分析、Log-rank检验以及Cox比例风险模型。结果将HBV相关HCC患者以血清AFP水平分为2组,AFP<400 ng/ml组IL-17的阳性表达率为50.9%（58/114）,AFP≥400 ng/ml组为34.0%（18/53）,2组比较差异有统计学意义（χ2=8.11,P=0.002）。AFP<400 ng/ml组和AFP≥400 ng/ml组患者术后无瘤生存期（34.1个月...
- 癌,肝细胞 /
- 甲胎蛋白类 /
- 白细胞介素17 /
- 预后
Abstract:
Objective To investigate the expression of interleukin-17 (IL-17) in hepatitis B virus (HBV) -related hepatocellular carcinoma (HCC) with different levels of alpha-fetoprotein (AFP) , as well as its association with recurrence and prognosis after radical treatment for HCC.Methods A total of 167 patients with HBV-related HCC who underwent radical resection in The Affiliated Tumor Hospital of Xinjiang Medical University from January 2013 to December 2014 were enrolled, and 115 patients with hepatic hemangioma (including 83 HBV carriers) were enrolled as control group.ELISA was used to measure the serum level of IL-17 in 167 patients with HBV-related HCC, and electrochemical luminescence was used to measure the serum level of AFP.The correlation between the expression of IL-17 and the serum level of AFP was analyzed, as well as the association of the expression of IL-17 with recurrence and survival after radical resection of HCC.The chi-square test was used for comparison of categorical data between groups, and the Kaplan-Meier method, log-rank test, and Cox proportional hazards model were used for survival analysis.Results The patients with HBV-related HCC were divided into two groups according to the serum level of AFP, and there was a significant difference in the positive expression rate of IL-17 between AFP <400 ng/ml group and AFP≥400 ng/ml group [50.9% (58/114) vs 34.0% (18/53) , χ2= 8.11, P = 0.002]; there were also significant differences between these two groups in disease-free survival (34.1 months vs 13.4 months, χ2= 10.34, P < 0.05) , overall survival (84.2 months vs 57.4 months, χ2= 3.13, P < 0.05) , and tumor recurrence rate within 1 year (28.9% vs 50.9%, χ2= 10.89, P <0.05) .The Kaplan-Meier analysis showed that among the patients with HBV-related HCC and AFP < 400 ng/ml, the patients with positive expression of IL-17 had a significantly higher recurrence rate within 1 year after surgery than those with negative expression of IL-17, as well as significantly shorter disease-free survival and overall survival than those with low expression of IL-17 (χ2= 7.350, 3.814, and9.744, all P < 0.05) .The Cox proportional hazards model showed that positive expression of IL-17, tumor thrombus in vessels, and degree of tumor differentiation were influencing factors for the prognosis of HCC patients (all P < 0.05) .Conclusion For patients with HBV-related HCC and AFP < 400 ng/ml, positive expression of IL-17 indicates early recurrence and poor prognosis.
- cacinoma, hepatocellular /
- alpha-fetoprotein /
- interleukin-17 /
- prognosis

HTML全文

参考文献(19)

[1]SUKOWATI GH, EL-KHOBA KE, LE SI, et al.Significance of hepatitis virus infection in the oncogenic initiation of hepatocellular carcinoa[J].World J Gastroenterol, 2016, 22 (4) :1497-1512.

[2]LIU XH, ZHAO YM, ZHAO XF, et al.Diagnostic and therapeutic progress on hepatocellular carcinoma[J/CD].Chin J Liver Dis:Electronic Edition, 2017, 9 (2) :20-25. (in Chinese) 刘秀红, 赵一鸣, 赵晓飞, 等.肝细胞癌诊断与治疗研究进展[J/CD].中国肝脏病杂志:电子版, 2017, 9 (2) :20-25.

[3]GEOFFREY J, MARKKOWITZ, GREGORY A, et al.Inflammatory models drastically alter tumor growth and the immune microenvironment in hepatocellular carcinoma[J].Sci Bull (Beijing) , 2015, 60 (8) :762-772.

[4]SOLINI M, KIRILOVSKY A, MLECNIK B, et al.Clinical impact of different glasses of infiltrating T cytotoxic and helper cells (Thl, th2, treg, thl7) in patients with colorectal cancer[J].Cancer Res, 2011, 71 (4) :1263-1271.

[5]STOCKINGER B, VELDHOEN M, MARTIN B, et al.Th17 T cells:linking innate andadaptive irnmunity[J].Semin Immunol, 2007, 19 (6) :353-361.

[6]EDGE SB, BYRD DR, COMPTON CC, et al.AJCC Cancer Staging Manual[M].7th ed.New York:Springer-Verlag, 2010.

[7]LANAYA H, NATARAJAN A, KOMPOSCH K, et al.EGFR has a tumourpromoting role in liver macrohages during hepatocellular carcinoma formation[J].Nat Cell Biol, 2014, 16 (10) :972-977.

[8]BERTINO G, ARDIRI A, MALAGUARNERA M, et al.Hepatocellualar carcinonm serunl markers[J].Semin Oncol, 2012, 39 (4) :410-433.

[9]YAMAMOTO K, IMAMURA H, MATSUYAMA Y, et al.AFP, AFP-L3, DCP, and GP73 as markers for monitoring treatment response and recurrence and as surrogate markers of clinicopathological variables of HCC[J].J Gastroenterol, 2010, 45 (12) :1272-1282.

[10]COLLI A, FRAQUELLI M, CASAZZA G, et al.Accuracy of ultrasonography, spiral CT, mag-netic resonance, and alpha-fetoprotein in diagnosing hepatocellular carcinoma:a systematic review[J].J Gastroenterol, 2006, 101 (3) :513-523.

[11]GAMBARIN-GELWAN M, WOLF DC, SHAPIRO R, et al.Sensitivity of commonly available screening tests in detecting hepatocellular carcinoma in hepatitis C virus cirrhosis[J].Hepatology, 2000, 95 (6) :1535-1538.

[12]LI JY, SONG JY, WANG JF, et al.Value of combined detection of AFP, CA19-9, CEA in early diagnosis of primary liver cancer[J].J Clin Hepatol, 2017, 33 (7) :1291-1295. (in Chinese) 李嘉妍, 宋金云, 王建芳, 等.AFP、CA19-9、CEA联合检测对原发性肝癌的早期诊断价值[J].临床肝胆病杂志, 2017, 33 (7) :1291-1295.

[13]BAE JS, PARK SJ, PARK KB, et al.Acute exacerbation of hepatitis in liver cirrhosis with very high levels of alpha-fetoprotein but no occurrence of hepatocellular carcinoma[J].Korean J Intern Med, 2005, 20 (1) :80-85.

[14]MA WJ, WANG HY, TENG LS, et al.Correlation analysis of preoperative serum alpha-fetoprotein (AFP) level and prognosis of hepatocellular carcinoma (HCC) after hepatectomy[J].World J Surg Oncol, 2013, 11:212.

[15]TU JF, PAN HY, YING XH, et al.Mast cells comprise the major of interleukin 17-producing cells and predict a poor prognosis in hepatocellular carcinoma[J].Medicine (Baltimore) , 2016, 95 (13) :e3220.

[16]AZZAZENE D, AL THAWADI H, AL FARSI H, et al.Plasma endothelial protein C receptor influences innate immune response in ovarian cancer by decreasing the population of natural killer and TH-17 helper cells[J].Int J Oncol, 2013, 43 (4) :1011-1018.

[17]DU WJ, ZHEN JH, ZENG ZQ, et al.Expression of interleukin-17 associatedwith disease progression and liver fibrosis with hepatitis B virus infection:IL-17 in HBV infection[J].Diagn Pathol, 2013, 8:40.

[18]REDA R, ABBAS AA, MOHAMMED M, et al.The interplay between Zinc, Vitamin D and IL-17 in patients with chronic hepatitis C liver disease[J].J Immunol Res, 2015, 2015:846348.

[19]LLOSA NJ, GEIS AL, THIELE ORBERG E, et al.Interleukin-17 and type 17 helper T cells in cancer management and research[J].Immunotargets Ther, 2014, 3:39-54.

施引文献

资源附件(0)

访问统计